Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition

27 Jun 2020

Abstract excerpt

The interaction of menin (MEN1) and MLL (MLL1, KMT2A) is a dependency and provides a potential opportunity for treatment of NPM1-mutant (NPM1mut) and MLL-rearranged (MLL-r) leukemias. Concomitant activating driver mutations in the gene encoding the tyrosine kinase FLT3 occur in both leukemias and are particularly common in the NPM1mut subtype. In this study, transcriptional profiling after pharmacological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32589720
DOI: 10.1182/blood.2020005037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibitionPMID 32589720Read ↗

Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.Semantic proximity Read ↗

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).Semantic proximity Read ↗

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1Semantic proximity Read ↗

Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in <i>KMT2A</i> r and <i>NPM1</i> -m AMLSemantic proximity Read ↗

Combination Strategies with Menin Inhibitors for Acute LeukemiaSemantic proximity Read ↗

Characterization of the Menin-MLL Interaction as Therapeutic Cancer TargetSemantic proximity Read ↗

Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.Semantic proximity Read ↗

Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?Semantic proximity Read ↗

Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AMLSemantic proximity Read ↗

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Semantic proximity Read ↗

Menin inhibitors in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.